New Doxycycline approved

[Guest guest]

to Market New Product Through General Products Division Sales Force

CORONA, Calif., and ROCKFORD, Ill., May 2 /PRNewswire/ --

Pharmaceuticals, Inc. (NYSE: WPI - news) and Halsey Drug Co., Inc. (Amex:

HDG - news) announced today that Halsey has received approval from the Food

and Drug Administration (FDA) for an abbreviated new drug application (ANDA)

for Doxycycline Capsules USP, 50 mg and 100 mg. In a previously announced

transaction, purchased this product and related assets from Halsey

for a purchase price of $13.5 million of which $5.0 million is to be paid to

Halsey within 30 days of the FDA approval of the ANDA.

Doxycycline is a broad-spectrum antibiotic, indicated for the treatment of

serious infections, such as, among others, upper respiratory tract, urinary

tract and Lyme disease. Halsey will manufacture and supply with this

antibiotic product, which plans to market as a brand pharmaceutical

product directly to the primary care physician marketplace by 's

150-person General Products sales force.

This press release may contain forward-looking statements relating to

's and Halsey's future business performance, which involve risks and

uncertainties that cannot be predicted or quantified. Consequently, actual

results may differ materially from those expressed or implied. Such risks

and uncertainties include, among others, those detailed in each of their

Securities and Exchange Commission filings.

Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the

development, manufacture and sale of proprietary and off-patent

pharmaceutical products.